Niaodukang for the treatment of chronic kidney disease: Regulation of the TRAF3/NF-κB2 signaling pathway and its improvement of the intestinal barrier
Tissue and Cell · 2026-04 · 99 · 103271
DOI: 10.1016/j.tice.2025.103271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tissue and Cell, 2026-04. Verfasst von Juan Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhon…. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Signal Transduction, TNF Receptor-Associated Factor 3, Drugs, Chinese Herbal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Tianjin Municipal Health Commission.
Abstract (Originalsprache)
BACKGROUND: Niaodukang (NDK) mixture is a traditional Chinese herbal formula clinically used for chronic kidney disease (CKD). However, its bioactive components and molecular mechanisms remain unclear. OBJECTIVE: To explore the protective effect of NDK on CKD-associated intestinal barrier dysfunction and identify its key active compound targeting the TRAF3/NF-κB2 pathway. METHODS: A 5/6 nephrectomy rat model and indole-induced Caco-2 cell injury model were established. Renal function, intestinal tight junction integrity, and inflammatory signaling were evaluated by histological, molecular, and ultrastructural analyses. Network pharmacology and molecular docking were applied to predict bioactive compounds, followed by in vitro validation. RESULTS: NDK significantly improved renal function (reduced Scr, BUN, and urine protein; P < 0.01) and restored intestinal epithelial barrier integrity, as indicated by increased ZO-1 and occludin expression and improved ultrastructure. Among 126 candidate compounds, formononetin from Astragalus membranaceus exhibited strong binding affinity to TRAF3. Functional assays confirmed that formononetin suppressed TRAF3/NF-κB2 signaling, restored tight junction proteins, and alleviated epithelial injury, whereas TRAF3 overexpression abolished these protective effects. CONCLUSION: NDK ameliorates CKD-associated intestinal barrier dysfunction by suppressing the TRAF3/NF-κB2 pathway. Formononetin serves as a principal active compound mediating this effect, elucidating the pharmacological basis of NDK and supporting its therapeutic potential for CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, Guangdong 528400, China; The Tenth Clinical Medical College of…
- Cardiovascular and Cerebrovascular Drugs Research and Development Center, Tianjin Institute of Medical and Pharmaceutical Sciences, Tianjin 300020, China.
- Pharmacokinetics Laboratory, Tianjin Institute of Medical and Pharmaceutical Sciences, Tianjin 300020, China.
- Department of Pathology, Tianjin Institute of Medical and Pharmaceutical Sciences, Tianjin 300020, China.
Förderung
- Tianjin Municipal Health Commission
Zitieren
APA
Xu, J., Wang, L., Wang, H., Pang, J., Liu, L., Zhang, T., Yuan, L., Cui, X., Jiang, Q., & Li, Y. (2026). Niaodukang for the treatment of chronic kidney disease: Regulation of the TRAF3/NF-κB2 signaling pathway and its improvement of the intestinal barrier. Tissue and Cell, 99, 103271. https://doi.org/10.1016/j.tice.2025.103271
Vancouver
Xu J, Wang L, Wang H, Pang J, Liu L, Zhang T, et al. Niaodukang for the treatment of chronic kidney disease: Regulation of the TRAF3/NF-κB2 signaling pathway and its improvement of the intestinal barrier. Tissue and Cell. 2026;99:103271. doi:10.1016/j.tice.2025.103271
BibTeX
@article{Xu2026,
author = {Xu, Juan and Wang, Lei and Wang, Hong and Pang, Jie and Liu, Linna and Zhang, Ting and Yuan, Ling and Cui, Xiaoxue and Jiang, Qian and Li, Yanlin},
title = {Niaodukang for the treatment of chronic kidney disease: Regulation of the TRAF3/NF-κB2 signaling pathway and its improvement of the intestinal barrier},
journal = {Tissue and Cell},
year = {2026},
volume = {99},
pages = {103271},
doi = {10.1016/j.tice.2025.103271}
}
EUVIMED